[Efficacy of anti-neuraminidase drugs application during and after an influenza pandemic].

[Efficacy of anti-neuraminidase drugs application during and after an influenza pandemic].

Voprosy virusologii (2013-06-22)

N V Breslav, E S Shevchenko, D D Abramov, A G Prilipov, M M Zhuravleva, T A Oskerko, L V Kolobukhina, L N Merkulova, M Iu Shchelkanov, E I Burtseva, D K L'vov

PMID23785758

ABSTRACT

The emergent 2009 A(H1N1) pandemic brought into acute focus the problem of choosing the most effective anti-influenza drugs for successive influenza infection spreading control. Oseltamivir and zanamivir, influenza virus neuraminidase inhibitors (NAIs), were recommended by the WHO experts for the treatment and prevention of influenza, including that caused by pandemic strains. A major concern regarding the use of specific antiviral compounds is the emergence of the drug-resistant strains. Oseltamivir carboxylate and zanamivir IC50 values were equal to 0.3-5.2 microM for the most of A(H1N1)pdm09 pandemic strains and 1.6-8.6 microM for the strains of influenza B virus in cell-based ELISA assay (2009-2010 season). All the studied strains of influenza A(H1N1 ) pdm09 (151) and B (22) viruses were sensitive to NAIs (2009-2011 seasons). For the first time in Russia oseltamivir-resistant A(H1N1) pdm09 influenza virus was isolated from the patient on the 5th day of a treatment course of this drug.

MATERIALS

Product Number

Brand

Product Description

N5631

Sigma-Aldrich

Neuraminidase from Clostridium perfringens (C. welchii), Type VIII, lyophilized powder, 10-20 units/mg protein (using 4MU-NANA), 3.5-8.0 units/mg protein (mucin)

N2876

Sigma-Aldrich

Neuraminidase from Clostridium perfringens (C. welchii), Suitable for manufacturing of diagnostic kits and reagents, Type V, lyophilized powder

N3001

Sigma-Aldrich

Neuraminidase from Clostridium perfringens (C. welchii), Type VI, lyophilized powder, 6-15 units/mg protein (using 4MU-NANA), 2-10 units/mg protein (mucin)

N2133

Sigma-Aldrich

Neuraminidase from Clostridium perfringens (C. welchii), Type X, lyophilized powder, ≥50 units/mg protein (using 4MU-NANA)

N7271

Sigma-Aldrich

α(2→3) Neuraminidase from Streptococcus pneumoniae, buffered aqueous solution

N5521

Sigma-Aldrich

α(2→3,6) Neuraminidase from Clostridium perfringens (C. welchii), recombinant, expressed in E. coli, buffered aqueous solution, ≥250 units/mg protein

N5254

Sigma-Aldrich

Neuraminidase Agarose from Clostridium perfringens (C. welchii), Type VI-A, ammonium sulfate suspension

N6514

Sigma-Aldrich

Neuraminidase from Vibrio cholerae, Type II, buffered aqueous solution, 8-24 units/mg protein (Lowry, using NAN-lactose)

N8271

Sigma-Aldrich

α(2→3,6,8,9) Neuraminidase from Arthrobacter ureafaciens, recombinant, expressed in E. coli, buffered aqueous solution

N3786

Sigma-Aldrich

α(2→3,6,8,9) Neuraminidase from Arthrobacter ureafaciens, Proteomics Grade, suitable for MALDI-TOF MS

N7885

Sigma-Aldrich

Neuraminidase from Vibrio cholerae, Type III, buffered aqueous solution, 0.2 μm filtered, 1-5 units/mg protein (Lowry, using NAN-lactose)

72197

Sigma-Aldrich

Neuraminidase from Vibrio cholerae, ≥1.5 U/mL, specific activity ≥ 1.5U/mg protein